Recent Preclinical and Clinical Progress in Liposomal Doxorubicin
Doxorubicin (DOX) is a potent anti-cancer agent that has garnered great interest in research due to its high efficacy despite dose-limiting toxicities. Several strategies have been exploited to enhance the efficacy and safety profile of DOX. Liposomes are the most established approach. Despite the i...
| Published in: | Pharmaceutics |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/15/3/893 |